Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00512681
Status:
COMPLETED
Last Update Posted:
2009-09-18
First Post:
2007-08-07
Brief Title:
A Phase II Study of Irinotecan Oxaliplatin Plus TS-1 in Untreated Metastatic Gastric Cancer
Sponsor:
National Cancer Center Korea
Organization:
National Cancer Center Korea
Study Overview
Official Title:
A Phase II Study of S-1 Combined With Irinotecan and Oxaliplatin in Recurrent or Metastatic Gastric Carcinoma
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TIROX2
Brief Summary:
Patients will be treated with irinotecan 150mgm2 followed by oxaliplatin 85mgm2on day 1 and S-180mgm2day from day 1 to 14 every 3 weeks Patients will receive up to a planned treatment of maximum 12 cycles of chemotherapy Response assessement will be performed every 2 cycles of chemotherapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None